Xilio Therapeutics (XLO) Price to Sales (2024 - 2026)

Xilio Therapeutics has disclosed Price to Sales across 3 years of filings, most recently posting 9.95 for Q2 2026.

• In Q2 2026, Price to Sales rose 22.6% year-over-year to 9.95; the TTM figure through Jun 2026 stood at 2.9 (down 33.65% YoY), while the FY2025 annual figure was 1.71, down 75.15% from the prior year.
• Price to Sales came in at 9.95 for Q2 2026 at Xilio Therapeutics, down from 10.87 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 25.35 in Q4 2024 to a low of 5.47 in Q4 2025.
• Average Price to Sales over 3 years is 14.43, with a median of 10.87 recorded in 2026.
• Year-over-year, Price to Sales plunged 78.4% in 2025 and grew 22.6% in 2026.
• Over 3 years, Price to Sales stood at 25.35 in 2024, then sank by 78.4% to 5.47 in 2025, then soared by 81.67% to 9.95 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 9.95 in Q2 2026, 10.87 in Q1 2026, and 5.47 in Q4 2025.